PTK2 and mesothelioma: However, a phase-II (registration-directed, double-blind, placebo-controlled study (COMMAND)) trial of another selective FAK inhibitor, VS-6063 (or defactinib), for use in patients with mesothelioma was recently halted, owing to a lack of any observed benefits (despite correcting for merlin deficiency).